Nuvalent reports Q1 EPS ($1.18), consensus $1.04

Cash, cash equivalents and marketable securities were $1.1B as of March 31. Nuvalent (NUVL) continues to believe its existing cash, cash equivalents and marketable securities will be sufficient to fund its current operating plan into 2028. “2025 is a critical year of execution for Nuvalent as we continue to transition toward becoming a fully integrated commercial-stage biopharmaceutical company,” said CEO James Porter. “We expect multiple meaningful milestones this year, including pivotal data for TKI pre-treated patients from both of our parallel lead programs, and our first potential NDA submission for zidesamtinib for TKI pre-treated patients with ROS1-positive NSCLC. The continued progress across our portfolio is a direct reflection of the strength and dedication of our team-it is their deep expertise, operational excellence, and commitment to patients that drive our ability to execute. In recognition of their significant contributions, we’re pleased to announce the leadership promotions of Ruth Adams to SVP, Clinical Operations; Dr. Joshua Horan to SVP, Chemistry; and Jessie Lin to SVP, Corporate Strategy and Portfolio Management. With strong product candidates, a solid financial position, and an experienced team unified by an unwavering commitment to patient impact, we believe we are well-positioned to achieve our goals.”